

# Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2020

<https://marketpublishers.com/r/I9B605CB5E1EN.html>

Date: April 2020

Pages: 503

Price: US\$ 2,000.00 (Single User License)

ID: I9B605CB5E1EN

## Abstracts

Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2020

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2020, provides an overview of the Idiopathic Pulmonary Fibrosis (Respiratory) pipeline landscape.

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease characterized by inflammation and scarring of lung tissue and loss of lung function. Symptoms of IPF include dry cough, shortness of breath, especially during or after physical activity, lasting tiredness and weight loss. Risk factors include smoking, environmental exposure, viral infections, family history and abnormal acid reflux. Treatment includes antioxidants, biological response modulators, anti-fibrotic agents and anticoagulants.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Idiopathic Pulmonary Fibrosis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Idiopathic Pulmonary Fibrosis (Respiratory) pipeline guide also reviews of key

players involved in therapeutic development for Idiopathic Pulmonary Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 3, 14, 30, 4, 95, 18 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 3 molecules, respectively.

Idiopathic Pulmonary Fibrosis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Idiopathic Pulmonary Fibrosis (Respiratory).

The pipeline guide reviews pipeline therapeutics for Idiopathic Pulmonary Fibrosis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Idiopathic Pulmonary Fibrosis (Respiratory) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Idiopathic Pulmonary Fibrosis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Idiopathic Pulmonary Fibrosis (Respiratory)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Idiopathic Pulmonary Fibrosis (Respiratory).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Idiopathic Pulmonary Fibrosis (Respiratory) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Idiopathic Pulmonary Fibrosis - Overview

Idiopathic Pulmonary Fibrosis - Therapeutics Development

Idiopathic Pulmonary Fibrosis - Therapeutics Assessment

Idiopathic Pulmonary Fibrosis - Companies Involved in Therapeutics Development

Idiopathic Pulmonary Fibrosis - Drug Profiles

Idiopathic Pulmonary Fibrosis - Dormant Projects

Idiopathic Pulmonary Fibrosis - Discontinued Products

Idiopathic Pulmonary Fibrosis - Product Development Milestones

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Idiopathic Pulmonary Fibrosis, H1 2020  
Number of Products under Development by Companies, H1 2020  
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020  
Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020  
Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020  
Number of Products under Development by Companies, H1 2020 (Contd..4), H1 2020  
Number of Products under Development by Companies, H1 2020 (Contd..5), H1 2020  
Number of Products under Development by Companies, H1 2020 (Contd..6), H1 2020  
Number of Products under Development by Universities/Institutes, H1 2020  
Products under Development by Companies, H1 2020  
Products under Development by Companies, H1 2020 (Contd..1), H1 2020  
Products under Development by Companies, H1 2020 (Contd..2), H1 2020  
Products under Development by Companies, H1 2020 (Contd..3), H1 2020  
Products under Development by Companies, H1 2020 (Contd..4), H1 2020  
Products under Development by Companies, H1 2020 (Contd..5), H1 2020  
Products under Development by Companies, H1 2020 (Contd..6), H1 2020  
Products under Development by Companies, H1 2020 (Contd..7), H1 2020  
Products under Development by Companies, H1 2020 (Contd..8), H1 2020  
Products under Development by Companies, H1 2020 (Contd..9), H1 2020  
Products under Development by Universities/Institutes, H1 2020  
Number of Products by Stage and Target, H1 2020  
Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020  
Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020  
Number of Products by Stage and Target, H1 2020 (Contd..3), H1 2020  
Number of Products by Stage and Target, H1 2020 (Contd..4), H1 2020  
Number of Products by Stage and Target, H1 2020 (Contd..5), H1 2020  
Number of Products by Stage and Mechanism of Action, H1 2020  
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020  
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020  
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..3), H1 2020  
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..4), H1 2020  
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..5), H1 2020  
Number of Products by Stage and Route of Administration, H1 2020  
Number of Products by Stage and Molecule Type, H1 2020  
Idiopathic Pulmonary Fibrosis - Pipeline by Abeome Corp, H1 2020

Idiopathic Pulmonary Fibrosis - Pipeline by Accendatech Au Pty Ltd, H1 2020

Idiopathic Pulmonary Fibrosis - Pipeline by AdAlta Ltd, H1 2020

Idiopathic Pulmonary Fibrosis - Pipeline by Afimmune Biopharma Ltd, H1 2020

Idiopathic Pulmonary Fibrosis - Pipeline by Algernon Pharmaceuticals Inc, H1 2020

Idiopathic Pulmonary Fibrosis - Pipeline by Altavant Sciences Inc, H1 2020

Idiopathic Pulmonary Fibrosis - Pipeline by Altay Therapeutics Inc, H1 2020

Idiopathic Pulmonary Fibrosis - Pipeline by Amgen Inc, H1 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Idiopathic Pulmonary Fibrosis, H1 2020  
Number of Products under Development by Companies, H1 2020  
Number of Products under Development by Universities/Institutes, H1 2020  
Number of Products by Top 10 Targets, H1 2020  
Number of Products by Stage and Top 10 Targets, H1 2020  
Number of Products by Top 10 Mechanism of Actions, H1 2020  
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020  
Number of Products by Top 10 Routes of Administration, H1 2020  
Number of Products by Stage and Top 10 Routes of Administration, H1 2020  
Number of Products by Top 10 Molecule Types, H1 2020  
Number of Products by Stage and Top 10 Molecule Types, H1 2020

### COMPANIES MENTIONED

Abeome Corp  
Accendatech Au Pty Ltd  
AdAlta Ltd  
Afimmune Biopharma Ltd  
Algernon Pharmaceuticals Inc  
Altavant Sciences Inc  
Altay Therapeutics Inc  
Amgen Inc  
Amplia Therapeutics Ltd  
AnaMar AB  
Angion Biomedica Corp  
Apaxen  
Aqua Therapeutics Co Ltd  
Aqualung Therapeutics Corp  
Ark Biosciences Inc  
Arroyo BioSciences LLC  
Asahi Kasei Pharma Corp  
AstraZeneca Plc  
Atrapos Therapeutics LLC  
AusBio Ltd  
Avalyn Pharma Inc



BerGenBio ASA  
Blade Therapeutics Inc  
Boehringer Ingelheim International GmbH  
Bonac Corp  
BreStem Therapeutics Inc  
Bristol-Myers Squibb Co  
Celdara Medical LLC  
CellCure  
Certa Therapeutics Pty Ltd  
Chiesi Farmaceutici SpA  
Chrysalis Pharma SAS  
Citryll BV  
CohBar Inc  
Collaborations Pharmaceuticals Inc  
Compugen Ltd  
CrystalGenomics Inc  
Daewoong Pharmaceutical Co Ltd  
EmphyCorp Inc  
Eptracker Inc  
Ergon Pharmaceuticals LLC  
ethris GmbH  
F. Hoffmann-La Roche Ltd  
FibroGen Inc  
FibroStatin SL  
Galapagos NV  
Galecto Biotech AB  
GenKyoTex SA  
Global Blood Therapeutics Inc  
Guangdong Zhongsheng Pharmaceutical Co Ltd  
HEC Pharm Co Ltd  
iBio Inc  
Imago Pharmaceuticals Inc  
Indalo Therapeutics Inc  
Inventiva  
iOnctura SA  
Ionis Pharmaceuticals Inc  
Isarna Therapeutics GmbH  
Iterion Therapeutics  
Jiangsu Hengrui Medicine Co Ltd

JW Pharmaceutical Corp  
Kadmon Corp LLC  
KBP BioSciences Co Ltd  
Kither Biotech Srl  
Kyorin Pharmaceutical Co Ltd  
Lamellar Biomedical Ltd  
LifeMax Laboratories Inc  
Lignamed LLC  
Liminal BioSciences Inc  
LTT Bio-Pharma Co Ltd  
Lung Therapeutics Inc  
Max Biopharma Inc  
MDI Therapeutics Inc  
Medicenna Therapeutics Corp  
Metagone Biotech Inc  
Metera Pharmaceuticals Inc  
Miragen Therapeutics Inc  
Mission Therapeutics Ltd  
Moerae Matrix Inc  
Morphic Holding Inc  
National Institutes of Pharmaceutical R&D Co Ltd  
NB Health Laboratory Co Ltd  
New Amsterdam Sciences Inc  
Nogra Pharma Ltd  
Novartis AG  
Novo Nordisk AS  
Nuformix Plc  
Oasis Pharmaceuticals LLC  
OliX Pharmaceuticals Inc  
OncoArendi Therapeutics SA  
Opsidio LLC  
OptiKira LLC  
OROX BioSciences Inc  
Osteoneurogen Inc  
Palo BioFarma SL  
Panorama Research Inc  
Pharmaxis Ltd  
Pharmicell Co Ltd  
Pliant Therapeutics Inc

Prasan Pharmaceutical Consultants LLC  
PRISM Pharma Co Ltd  
Pulmatrix Inc  
RDS2 Solutions Inc  
Re-Pharm Ltd  
Redx Pharma Plc  
Regenasome Pty Ltd  
Rejuvenation Technologies Inc  
Reviva Pharmaceuticals Inc  
Ribomic Inc  
Roivant Sciences Ltd  
Saje Pharma LLC  
Samumed LLC  
Segue Therapeutics LLC  
Shionogi & Co Ltd  
Sichuan Haisco Pharmaceutical Co Ltd  
Silurian Pharmaceuticals Inc  
Suzhou Zelgen Biopharmaceutical Co Ltd  
SynDevRx Inc  
Taiho Pharmaceutical Co Ltd  
TaiwanJ Pharmaceuticals Co Ltd  
Telocyte LLC  
Theravance Biopharma Inc  
TiumBio Co Ltd  
TRACON Pharmaceuticals Inc  
Translate Bio Inc  
Unity Biotechnology Inc  
Vectus Biosystems Ltd  
Vicore Pharma AB  
X-Rx Inc  
Xfibra Inc  
Yungjin Pharm Co Ltd  
Zai Lab Ltd

## I would like to order

Product name: Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/I9B605CB5E1EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/I9B605CB5E1EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970